564
ZU DONG LIU ET AL
Choudhury, R. (1995) Metabolism and Pharmacokinetics of 1-
Hydroxyalkyl-3-hydroxypyridin-4-one Chelating Agents.
Ph.D. Thesis, King's College, London
Porter, J. B., Morgan, J., Hoyes, K. P., Burke, L. C., Huehns, E.
R., Hider, R. C. (1990a) Relative oral ef®cacy and acute
toxicity of hydroxypyridin-4-one iron chelators in mice.
Blood 76: 2389±2396
Porter, J. B., Huehns, E. R., Hider, R. C. (1990b) Update on
the hydroxypyridinone oral-iron chelating agents. Seminars
in Haematology 27: 95±100
Porter, J. B., Abeysinghe, R. D., Hoyes, K. P., Barra, C.,
Huehns, E. R., Brooks, P.N., Blackwell, M. P., Araneta, M.,
Britenham, G., Singh, S., Dobbin, P., Hider, R. C. (1993)
Contrasting interspecies ef®cacy and toxicology of 1,2-
diethyl-3-hydroxypyridin-4-one CP94, relates to differing
metabolism of the iron chelating site. Br. J. Haematol. 85:
159±168
Porter, J. B., Singh, S., Katherine, P. H., Epemolu, O.,
Abeysinghe, R. D., Hider, R. C. (1994) Lessons from
preclinical and clinical studies with 1,2-diethyl-3-hydroxy-
pyridin-4-one, CP94 and related compounds. Adv. Exp.
Med. Biol. 356: 361±370
Rai, B. L., Dekhordi, L. S., Khodr, H., Jin, Y., Liu, Z., Hider,
R. C. (1998) Synthesis, physicochemical properties and
evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyri-
dinones. J. Med. Chem. 41: 3347±3359
Rai, B. L., Liu, Z. D., Liu, D. Y., Lu, S. L., Hider, R. C. (1999)
Synthesis, physicochemical properties and biological eva-
luation of ester prodrugs of 3-hydroxypyridin-4-ones: design
of orally active chelators with clinical potential. Eur. J. Med.
Chem. In press
Choudhury, R., Epemolu, R. O., Rai, B. L., Hider, R. C.,
Singh, S. (1997) Metabolism and pharmacokinetics of 1-(20-
trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one
(CP117) in the rat. Drug Metab. Disposit. 25: 332±339
Holme, E., Greter, J., Jacobson, C. E., Nordin, I., Lindstedt, S.,
Kristiansson, B. (1989) Carnitine de®ciency induced by
pivampicillin and pivampicillinam therapy. Lancet ii:
469±472
Holme, E., Jodal, U., Linstedt, S., Nordin, I. (1992) Effects of
pivalic acid-containing prodrugs on carnitine homeostasis
and on response to fasting in children. Scand. J. Clin. Invest.
52: 361±372
Jin, Y., Singh, S., Epemolu, R. O., Porter, J. B., Hider, R. C.,
Nick, H. P., Bergeron, R. J., Wiegand, J., Schnebli, H. P.
(1993) CP102; a potent orally active iron chelator. Proceed-
ings of the European Iron Club Meeting, London
Liu, Z. D., Lu, S. L., Hider, R. C. (1999) In-vivo iron
mobilisation evaluation of hydroxypyridinones in 59Fe-fer-
ritin loaded rat model. Biochem. Pharmacol. 57: 559±566
Melegh, B., Kerner, J., Bieber, L. L. (1987) Pivampicillin-
promoted excretion of pivaloylcarnitine in humans. Bio-
chem. Pharmacol. 36: 3405±3409
Mitsunobu, O. (1981) The use of diethylazodicarboxylate and
triphenylphosphine in synthesis and transformation of nature
products. Synthesis 1: 1±28
Oliveri, N. F., Koren, G., Matsui, D., Liu, P. P., Blendis, L.,
Cameron, R., McClelland, R. A., Templeton, D. M. (1992)
Reduction in tissue iron stores and normalisation of serum
ferritin during treatment with the oral iron chelator L1 in
thalassaemia intermedia. Blood 79: 2741±2748
Singh, S., Epemolu, O., Dobbin, P. S. Tilbrook, G. S., Ellis, B.
L., Damani, L. A. Hider, R. C. (1992a) Urinary metabolic
pro®les in man and rat of 1,2-dimethyl- and 1,2-diethyl
substituted 3-hydroxypyridin-4-ones. Drug Metab. Disposit.
20: 256±261
Pippard, M. J., Callender, S. T., Letsky, E. A., Weatherall, D.
J. (1978a) Prevention of iron loading in transfusion-depen-
dent thalassaemia. Lancet i: 1178±1180
Pippard, M. J., Callender, S. T., Weatherall, D. J. (1978b)
Intensive iron-chelation therapy with desferrioxamine in
iron-loading anaemias. Clin. Sci. Mol. Med. 54: 99±106
Pippard, M. J., Johnson, D. K., Finch, C. A. (1981) A rapid
assay for evaluation of iron chelating agents in rats. Blood
58: 685±692
Poon, K., Pang, K. S. (1995) Benzoic acid glycine conjugation
in the isolated perfused rat kidney. Drug Metab. Disposit.
23: 255±260
Porter, J. B., Huehns, E. R., Hider, R. C. (1989) The develop-
ment of iron chelating drugs. Bailliere's Clin. Haematol. 2:
257±292
Singh, S., Epemolu, R. O., Ackerman, R., Porter, J. B.,
Hider, R. C. (1992b) Development of 3-hydroxypyridin-4-
ones which do not undergo extensive phase II metabolism.
3rd NIH-Sponsored Symposium on The Development of
Iron Chelators for Clinical Use, Gainsville, FL, Abstract
No. 52
Singh, S., Choudhury, R., Epemolu, R. O., Hider, R. C. (1996)
Metabolism and pharmacokinetics of 1-(20-hydroxyethyl)-
and 1-(30-hydroxypropyl)-2-ethyl-3-hydroxypyridin-4-ones
in the rat. Eur. J. Drug Metab. Pharmacokinet. 21: 33±41
Tilbrook, G. S., Hider, R. C. (1998) Iron chelators for clinical
use. In: Sigel, A., Sigel, H. (eds) Metal Irons in Biological
Systems. Vol. 35. Iron Transport and Storage in Microor-
ganisms, Plants and Animals. Marcel Dekker, New York, pp
691±730